Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: a report of the Atlantic Collaborative Intravenous Immune Globulin Utilization Working Group
- 19 July 2007
- journal article
- Published by Wiley in Transfusion
- Vol. 47 (11) , 2072-2080
Abstract
Intravenous immunoglobulin (IVIG) use for labeled and unlabeled indications is growing steadily. By use of a collaborative regional strategy, baseline IVIG usage and appropriateness of utilization were determined for Atlantic Canada. The effectiveness of strategies designed to optimize utilization was also studied. A regional working group was created to monitor IVIG utilization for a 2-year period in the four Canadian Atlantic Provinces. A registry of IVIG was created. Assessment of indication appropriateness was determined with national and provincial guidelines along with expert clinical opinion. To optimize IVIG use, IVIG guidelines and feedback reports were distributed to stakeholders. Appropriateness of IVIG use was compared over the course of the study. The leading indications for IVIG use were idiopathic thrombocytopenic purpura (17.3%), primary immune deficiency conditions (14.9%), and chronic idiopathic demyelinating polyneuropathy (11.8%). The leading prescribing specialists were neurologists (32.2%) and hematologists (26.1%). A total of 37.1 percent of IVIG usage was in accordance with labeled indications. After optimization strategies were implemented, there was little change in labeled use. There was a 4.2 percent decrease in unlabeled use not supported by evidence (p<0.001). A regional collaborative strategy for monitoring IVIG use was established. Most of the IVIG use was for labeled or appropriate indications. The majority of unlabeled use was supported by the medical literature. Strategies to optimize IVIG utilization were associated with a decrease in inappropriate IVIG use and a plateau in IVIG utilization compared to the rest of the country.Keywords
This publication has 8 references indexed in Scilit:
- Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic reviewTransfusion, 2005
- Clinical uses of intravenous immunoglobulinClinical and Experimental Immunology, 2005
- Therapeutic intravenous immunoglobulinsMolecular Immunology, 2005
- IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of lifeThrombosis and Haemostasis, 2004
- Risks associated with the use of intravenous immunoglobulin 1 1This review article reflects the opinions of the authors and not necessarily those of the U.S. Food and Drug Administration.Transfusion Medicine Reviews, 2003
- Intravenous immunoglobulin: regulatory perspectives on use and supplyTransfusion Medicine, 2001
- A Multicenter Drug Use Surveillance of Intravenous Immunoglobulin Utilization in US Academic Health CentersAnnals of Pharmacotherapy, 2000
- Improving utilization of intravenous immune globulin through concurrent use of an indication formEuropean Journal of Clinical Pharmacology, 1997